Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | GNRHR | P30968 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4013940 | 0.89 | MAPT (0.52) | MAPTKMT2AMEN1CYP3A4CYP2D6 | |
| SCHEMBL4005289 | 0.86 | NAMPT (0.60) | MAPTKMT2AMEN1CYP3A4CYP2D6 | |
| SCHEMBL14399794 | 0.81 | MAPT (0.47) | MAPTKMT2AMEN1CYP3A4CYP2D6 | |
| SCHEMBL4012337 | 0.79 | MAPT (0.74) | MAPTKMT2AMEN1CYP3A4CYP2D6 | |
| SCHEMBL13688474 | 0.77 | GNRHR (0.57) | MAPTKMT2AMEN1CYP3A4CYP2D6 | |
| SCHEMBL4013113 | 0.76 | MAPT (0.49) | MAPTKMT2AMEN1CYP3A4CYP2D6 | |
| SCHEMBL13688472 | 0.75 | GNRHR (0.55) | MAPTKMT2AMEN1CYP3A4CYP2D6 | |
| SCHEMBL13688476 | 0.75 | GNRHR (0.55) | MAPTKMT2AMEN1CYP3A4CYP2D6 | |
| SCHEMBL13688475 | 0.74 | GNRHR (0.55) | MAPTKMT2AMEN1CYP3A4CYP2D6 | |
| SCHEMBL13688468 | 0.74 | GNRHR (0.58) | MAPTKMT2AMEN1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | ALLEN JENNIFER REBECCA | 2008-11-20 | — | — | US | disclosed |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | ALLEN JENNIFER REBECCA | 2008-11-20 | — | — | US | disclosed |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | ALLEN JENNIFER REBECCA | 2008-11-20 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088018-A1 | Cb1 antagonist compounds | CNR1, CNR2, CHRNA5 | MAPT 542/4885KMT2A 2691/4885MEN1 157/4885 |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | CNR1, CNR2, MAG | MAPT 548/4885KMT2A 2789/4885MEN1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.